Clinical Trial Update: Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase [Phase 2]

View source ↗

Summary

A Phase 2 exploratory study evaluating high-dose imatinib in intermediate-risk chronic myeloid leukemia in chronic phase has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: University of Bologna | Conditions: Myeloid Leukemia, Chronic, Chronic-Phase | Phase 2 | Status: COMPLETED